Toronto, Ontario--(Newsfile Corp. - November 30, 2022) - LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("LevelJump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce today it has reported financial results for the third fiscal quarter ended September 30, 2022. All amounts are expressed in Canadian dollars.
Financial and Operational Highlights
Q3 Adjusted EBITDA of $0.001 per share.
Annual run rate is projected at over $12 million for 2023, including investments in associates at over $15 million.
Revenues from Canadian Teleradiology Services, Inc. ("CTS") operations remain strong with $2,296,186 in revenues for the third quarter.
Gross profit from CTS operations was $647,146 for the quarter, a 28.2% margin;
Year over Year Q3 revenue increase of $556,721 an increase of 32%.
Financial Guidance
Management is currently estimating adjusted EBITDA of approximately $0.005 per share for Fiscal Year 2022 and approximately $0.016 for Fiscal Year 2023.
Management Comments
"Revenues continue to increase as we implement our growth strategy of acquisition coupled with organic growth," said Mitch Geisler, CEO. "We are forecasting increased adjusted EBITDA, leading to profitability as we move into 2023. Our in-patient care clinics along with our telehealth operations have allowed us to become a critical care healthcare company with multiple revenue streams."
Non-GAAP Financial Measures
This news release contains financial terms (such as adjusted EBITDA) that are not considered under GAAP. Such financial measures, together with measures prepared in accordance with GAAP, provide useful information to investors and shareholders, as management uses them to evaluate the operating performance of the Company. The Company's determination of these non-GAAP measures may differ from other reporting issuers, and therefore are unlikely to be comparable to similar measures presented by other companies. Further, these non-GAAP measures should not be considered in isolation or as a substitute for measures of performance or cash flows prepared in accordance with GAAP. These financial measures are included because management uses this information to analyze operating performance and liquidity. For more information with respect to financial measures which have not been defined by GAAP, see the "Non-GAAP Measures and Other Financial Measures" section of the Company's Management Discussion and Analysis ("MD&A") for the quarter ending September 30, 2022 available on the Company's website (www.leveljumphealthcare.com) and under the Company's profile on SEDAR (www.sedar.com).
Adjusted EBITDA & Annual Revenue Run Rate
Management believes adjusted EBITDA is a useful supplemental measure to determine the Company's ability to generate cash available for working capital, capital expenditures, debt repayments, interest expense and income taxes.
EBITDA refers to net income (loss) determined in accordance with GAAP, before depreciation and amortization, net interest expense (income) and income tax expense (recovery). The Company defines adjusted EBITDA as EBITDA, plus stock-based compensation expense, restructuring, fair value adjustments, listing expense and transaction costs, impairment, and finance income.
A reconciliation of adjusted EBITDA to net income (loss) is as follows:
Three Months ended September 30 | |||
($ in thousands) | 2022 | 2021 | |
Net income (loss) and comprehensive income (loss) | (210) | (419) | |
Add back: | |||
Depreciation and amortization | 51 | 8 | |
Net interest expense | 40 | 2 | |
Stock-based compensation | 37 | 105 | |
Misc and foreign exchange | 3 | (38) | |
EBITDA | (79) | (342) | |
Add back: | |||
One-time Professional Fees | 150 | 50 | |
Adjusted EBITDA | 71 | (292) |
For further details on the results, please refer to LevelJump's interim MD&A and Unaudited Condensed Interim Consolidated Financial Statements for the quarter ended September 30, 2022, which are available on the Company's website (www.leveljumphealthcare.com) and under the Company's profile on SEDAR (www.sedar.com).
About LevelJump Healthcare
LevelJump Healthcare Corp., (TSXV: JUMP) is building a national telehealth medical company and brand, currently by providing teleradiology (remote radiology) services to its client hospitals and imaging centers. Additionally, JUMP owns and operates independent healthcare facilities (IHF's) focused on diagnostic imaging.
ON BEHALF OF THE BOARD OF DIRECTORS OF
LEVELJUMP HEALTHCARE CORP.
Mitchell Geisler, Chief Executive Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
(833) 840-2020
Cautionary Note Regarding Forward-Looking Statements
This news release may contain "forward-looking information" within the meaning of applicable securities laws relating to the Company's business plans and the outlook of the Company's industry. Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, Canadian Teleradiology Services, Inc., their securities, or their respective financial or operating results (as applicable).
Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.
Last Trade: | C$0.05 |
Daily Volume: | 0 |
Market Cap: | C$4.820M |
September 03, 2024 August 30, 2024 August 29, 2024 August 28, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB